List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 152 studies with search of: "Multiple Sclerosis, Relapsing-Remitting"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed A Study to Evaluate Rebif® New Formulation (IFN-beta-1a) in Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif® New Formulation (IFN-beta-1a)
2 Active, not recruiting
Has Results 		A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: interferon beta-1a (Rebif®);   Biological: alemtuzumab
3 Recruiting Safety and Efficacy Study of Daclizumab HYP to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: daclizumab HYP;   Other: placebo
4 Completed A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Rebif® 44 mcg three times per week subcutaneously (SubQ);   Drug: Avonex® 30 mcg once weekly intramuscularly (IM)
5 Completed
Has Results 		Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Betaseron (Interferon beta 1b, BAY86-5046)
6 Completed Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
7 Active, not recruiting Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon-1beta (Betaseron, BAY86-5046)
8 Recruiting A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients "TIMER" Study
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Natalizumab (Tysabri®)
9 Completed BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: BHT-3009 0.5 mg;   Drug: BHT-3009 1.5 mg;   Drug: Placebo
10 Completed Atorvastatin in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: interferon beta treatment to add-on atorvastatin treatment;   Drug: untreated to atorvastatin treatment
11 Completed A Study for Patients With Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: dirucotide;   Drug: placebo
12 Recruiting A Study of Patients With Relapsing Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: LY2127399;   Drug: Placebo
13 Not yet recruiting High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Cyclophosphamide/Glatiramer acetate
14 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
15 Active, not recruiting Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
16 Completed Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: Human interferon beta-1a and glatiramer acetate
17 Active, not recruiting Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
18 Enrolling by invitation Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
19 Recruiting ACT-128800 in Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: ACT-128800;   Drug: Placebo
20 Recruiting Safety and Efficacy Extension Study of Daclizumab HYP to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab HYP

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services